13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • NIAGARA

    Acronym: 

    NIAGARA

    ACTRN/NCT /ethics: 

    NCT03732677

    Scientific title: 

    Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

    Summary of trial and patient characteristics

    Cancer Type Bladder
    Trial Type Treatment
    Phase Phase III Tumour Stream Bladder cancer
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2018-11-16
    Molecular Target Anticipated End Date 2025-12-18
    Cancer Type Bladder
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Bladder cancer
    Cancer Stage All stages
    Anticipated Start Date 2018-11-16
    Anticipated End Date 2025-12-18

    Trial Summary

    A phase III, randomised, opem-label, multi-center, global study to determine the efficacy and safety of durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer

    Lay Summary

    Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

    Sponsor / Cooperative group

    AstraZeneca

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Lyell McEwin Hospital Andy Phay andy.phay@sa.gov.au 08 8282 0833 Dr Christopher Hocking Recruiting